BACKGROUND: the OAT found that routine late (3-28 days post-myocardial infarction) percutaneous coronary intervention (PCI) of an occluded infarct-related artery did not reduce death, reinfarction, or heart failure relative to medical treatment (MED). Angina rates were lower in PCI early, but the advantage over MED was lost by 3 years. METHODS:angina and revascularization status were collected at 4 months, then annually. We assessed whether non-protocol revascularization procedures in MED accounted for loss of the early symptomatic advantage of PCI. RESULTS: seven per 100 more PCI patients were angina-free at 4 months (P < .001) and 5 per 100 at 12 months (P = .005) with the difference narrowing to 1 per 100 at 3 years (P = .34). Non-protocol revascularization was more frequent in MED (5-year rate 22% vs 19% PCI, P = .05). Indications for revascularization included acute coronary syndromes (39% PCI vs 38% MED), stable angina/inducible ischemia (39% in each group), and physician preference (17% PCI vs 15% MED). Revascularization rates among patients with angina at any time during follow-up (35% of cohort) did not differ by treatment group (5-year rates 26% PCI vs 28% MED). Most symptomatic patients were treated without revascularization during follow-up (77%). CONCLUSIONS: in a large randomized clinical trial of stable post-myocardial infarction patients, the modest benefit on angina from PCI of an occluded infarct-related artery was lost by 3 years. Revascularization was slightly more common in MED during follow-up but was not driven by acute ischemia, and almost 1 in 5 procedures were attributed to physician preference alone.
RCT Entities:
BACKGROUND: the OAT found that routine late (3-28 days post-myocardial infarction) percutaneous coronary intervention (PCI) of an occluded infarct-related artery did not reduce death, reinfarction, or heart failure relative to medical treatment (MED). Angina rates were lower in PCI early, but the advantage over MED was lost by 3 years. METHODS:angina and revascularization status were collected at 4 months, then annually. We assessed whether non-protocol revascularization procedures in MED accounted for loss of the early symptomatic advantage of PCI. RESULTS: seven per 100 more PCI patients were angina-free at 4 months (P < .001) and 5 per 100 at 12 months (P = .005) with the difference narrowing to 1 per 100 at 3 years (P = .34). Non-protocol revascularization was more frequent in MED (5-year rate 22% vs 19% PCI, P = .05). Indications for revascularization included acute coronary syndromes (39% PCI vs 38% MED), stable angina/inducible ischemia (39% in each group), and physician preference (17% PCI vs 15% MED). Revascularization rates among patients with angina at any time during follow-up (35% of cohort) did not differ by treatment group (5-year rates 26% PCI vs 28% MED). Most symptomatic patients were treated without revascularization during follow-up (77%). CONCLUSIONS: in a large randomized clinical trial of stable post-myocardial infarctionpatients, the modest benefit on angina from PCI of an occluded infarct-related artery was lost by 3 years. Revascularization was slightly more common in MED during follow-up but was not driven by acute ischemia, and almost 1 in 5 procedures were attributed to physician preference alone.
Authors: Kim A Eagle; Shaun G Goodman; Alvaro Avezum; Andrzej Budaj; Cynthia M Sullivan; José López-Sendón Journal: Lancet Date: 2002-02-02 Impact factor: 79.321
Authors: Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Thomas M Maddox; Kimberly J Reid; John A Spertus; Murray Mittleman; Harlan M Krumholz; Susmita Parashar; P Michael Ho; John S Rumsfeld Journal: Arch Intern Med Date: 2008-06-23
Authors: Daniel B Mark; Wenqin Pan; Nancy E Clapp-Channing; Kevin J Anstrom; John R Ross; Rebecca S Fox; Gerard P Devlin; C Edwin Martin; Christopher Adlbrecht; Patricia A Cowper; Linda Davidson Ray; Eric A Cohen; Gervasio A Lamas; Judith S Hochman Journal: N Engl J Med Date: 2009-02-19 Impact factor: 91.245
Authors: Marc Cohen; Gian Franco Gensini; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Maria Krzeminska-Pakula; Jose Santopinto; Carole Hecquet; Luc Vittori Journal: Circulation Date: 2003-10-21 Impact factor: 29.690
Authors: Robert A Henderson; Stuart J Pocock; Tim C Clayton; Rosemary Knight; Keith A A Fox; Desmond G Julian; Douglas A Chamberlain Journal: J Am Coll Cardiol Date: 2003-10-01 Impact factor: 24.094
Authors: Vladimír Dzavík; Christopher E Buller; Gerard Devlin; Ronald G Carere; G B John Mancini; Warren J Cantor; Pawel E Buszman; James M Rankin; Carlos Vozzi; John R Ross; Sandra Forman; Bruce A Barton; A Gervasio A Lamas; Judith S Hochman Journal: Catheter Cardiovasc Interv Date: 2009-05-01 Impact factor: 2.692
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Judith S Hochman; Harmony R Reynolds; Vladimír Dzavík; Christopher E Buller; Witold Ruzyllo; Zygmunt P Sadowski; Aldo P Maggioni; Antonio C Carvalho; James M Rankin; Harvey D White; Suzanne Goldberg; Sandra A Forman; Daniel B Mark; Gervasio A Lamas Journal: Circulation Date: 2011-10-24 Impact factor: 29.690